Invention Grant
- Patent Title: Antibodies against HER2 truncated variant CTF-611
- Patent Title (中): 针对HER2截短型CTF-611的抗体
-
Application No.: US12961004Application Date: 2010-12-06
-
Publication No.: US08741586B2Publication Date: 2014-06-03
- Inventor: Joaquin Arribas Lopez , Kim Pedersen , Pier-Davide Angellini , Josep Lluis Parra Palau , Jose Baselga Torres
- Applicant: Joaquin Arribas Lopez , Kim Pedersen , Pier-Davide Angellini , Josep Lluis Parra Palau , Jose Baselga Torres
- Applicant Address: ES Barcelona ES Barcelona
- Assignee: Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats,Fundacio Privada Institut d'Investigacio Oncologica de vall d'Hebron
- Current Assignee: Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats,Fundacio Privada Institut d'Investigacio Oncologica de vall d'Hebron
- Current Assignee Address: ES Barcelona ES Barcelona
- Agency: McAndrews, Held & Malloy
- Priority: EP09380183 20091207
- Main IPC: C12P21/08
- IPC: C12P21/08 ; C07K16/30 ; C07K16/28 ; G01N33/574 ; G01N33/573 ; G01N33/567 ; G01N33/50
Abstract:
The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor.The invention provides antibodies or fragments thereof that recognise an epitope of the HER2 receptor truncated form CTF-611, said epitope being defined by a sequence included in SEQ ID NO: 2, and that are capable of discriminating between CTF-611 and CTF-616 (represented by SEQ ID NO:7), preferably additionally capable of discriminating between CTF-611 and CTF-613 (represented by SEQ ID NO:6).The invention also provides a method of cancer diagnosis using the disclosed antibodies, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.
Public/Granted literature
- US20110135653A1 Antibodies Against HER2 Truncated Variant CTF-611 Public/Granted day:2011-06-09
Information query
